Early interim PET scan in Hodgkin lymphoma: where do we stand?
Positron emission tomography using [18F]-fluoro-2-deoxy-d-glucose (FDG-PET) is an important tool for staging and treatment response assessment in malignant lymphomas. In Hodgkin lymphoma (HL), FDG-PET precisely predicts the therapy response when performed very early during standard ABVD chemotherapy. However, it is unclear whether FDG-PET retains this role if therapy is changed as a consequence of the scan, or if performed during a more intensive chemotherapy regimen such as BEACOPPesc, which is used for HL. This brief review presents the up-to-date evidence for the use and interpretation of early interim FDG-PET in HL, including recent preliminary results on early interim FDG-PET during BEACOPPesc therapy.
Gallamini
Andrea
A
Hematology Department Az. Ospedaliera S. Croce e Carle, Cuneo, Italy. gallamini.a@ospedale.cuneo.it
Hutchings
Martin
M
Avigdor
Abraham
A
Polliack
Aaron
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D049268:Positron-Emission Tomography / Q000379:methods*
D019788:Fluorodeoxyglucose F18